Netherlands-based Mylan said it also intends to continue to market and distribute branded EpiPen. Mylan's shares were up about 1 percent at $43.53 in premarket trading. The stock had fallen 12 percent last week.
RadioShack (NYSE: RSH) 35.5% HIGHER; is said to have reached an agreement with a consortium led by Standard General with respect to a $590 million financing agreement. Durata Therapeutics (NASDAQ: DRTX) 10% HIGHER; …
HERTFORDSHIRE, England and PITTSBURGH, Nov. 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange …
Its Pharmaloz subsidiary will manufacture and supply the Cold-Eeze products to Mylan. ProPhase's executive officers have agreed to vote the 24.1 percent of company stock they own in favor of the deal. The 20-year-old Cold-Eeze brand …
Mylan is the worst-performing stock in the 61-member S&P 500 health-care index over the past 12 months with a 39 percent slump. Perrigo Co., another maker of generics, saw the second-biggest decline at 32 percent, while the …
NEW YORK — Teva has offered to buy Mylan in a cash-and-stock deal valued at about $40.1 billion. The potential combination would result in a powerhouse of a generic drug developer competing against rivals such as Sun Pharma. …
Mylan shares have fallen slightly more than 6 percent since the beginning of the year, while the Standard & Poor's 500 index has risen 16 percent. The stock has risen 2 percent in the last 12 months. This story was generated by …
Last month, in a major blow to Teva, Mylan MYL launched (at-risk ... But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have …